TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1657](Hepatitis C virus genotype 1a (isolate 1) (HCV))
Gilead Sciences
US Patent
Gilead Sciences
US Patent
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Inhibition assay using HCV protease.More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
Affinity DataIC50: <10nMAssay Description:Compounds of the present invention were prepared into 10 mM DMSO solution and 10 nL of stock was transferred into 384 plates (Optiplate 384 plate) us...More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)